Allakos Inc. (ALLK)

Market Cap	29.74M
Revenue (ttm)	n/a
Net Income (ttm)	-70.85M
Shares Out	90.38M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	725,841
Open	0.3283
Previous Close	0.3293
Day's Range	0.3283 - 0.3295
52-Week Range	0.2200 - 1.5600
Beta	0.14
Analysts	Hold
Price Target	2.00 (+507.72%)
Earnings Date	May 27, 2025

About ALLK

Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company was incorporated in 2012 and is headquartered in San Carlos, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 2018
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLK
• Website: https://www.allakos.com

Analyst Summary

According to 3 analysts, the average rating for ALLK stock is "Hold." The 12-month stock price target is $2.0, which is an increase of 507.72% from the latest price.

Price Target

$2.0

(507.72% upside)

Analyst Consensus: Hold